Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.76 |
| ▸ | MEN1 | O00255 | 8/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819400 | 0.83 | DRD2 (0.55) | KMT2AMEN1ATMMAPK1CHRM4 | |
| SCHEMBL6352566 | 0.80 | MEN1 (0.86) | KMT2AMEN1ATMMAPK1CHRM4 | |
| SCHEMBL5670605 | 0.80 | KMT2A (0.48) | KMT2AMEN1ATMMAPK1BCHE | |
| SCHEMBL5245576 | 0.79 | MEN1 (0.74) | KMT2AMEN1ATMMAPK1CHRM4 | |
| SCHEMBL6927533 | 0.78 | CCNT1 (0.50) | KMT2AMEN1CCNT1CDK9CHRM4 | |
| SCHEMBL8034282 | 0.78 | MEN1 (0.82) | KMT2AMEN1ATMMAPK1CHRM4 | |
| SCHEMBL24595061 | 0.78 | HTR2C (0.47) | CHRM4 | |
| SCHEMBL6906362 | 0.76 | MEN1 (0.75) | KMT2AMEN1ATMMAPK1CHRM4 | |
| SCHEMBL27511358 | 0.73 | DRD2 (0.59) | KMT2AMEN1ATMMAPK1DRD2 | |
| SCHEMBL6907959 | 0.73 | MEN1 (0.63) | KMT2AMEN1ATMBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1648868-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | KMT2A 1131/4885MEN1 4395/4885ATM 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.